Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Documentation of the Utilization of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions (LAPIS-Pso)

NCT02626793 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02626793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02626793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Documentation of the Utilization of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions (LAPIS-Pso)
Lead sponsor
Amgen
Phase
Observational
Overall status
Completed
Start date
August 3, 2015
Completion date
June 14, 2018
Enrollment
391 (actual)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis